Guardant Health Inc (NASDAQ:GH) delivered a strong finish to its fiscal year, posting fourth-quarter revenue that exceeded Wall Street's expectations and providing an optimistic outlook for 2026. The precision oncology company's results, released after the market close on Thursday, February 19, 2026, were met with a positive initial reaction in after-hours trading.
Top-Line Strength and Bottom-Line Progress
The company's fourth-quarter performance was driven by robust growth across its core business segments. Revenue for the quarter reached $281.3 million, a significant 39% increase compared to the same period in 2024. This figure surpassed analyst estimates, which had projected revenue of approximately $278.6 million.
The company's bottom-line results also showed improvement on an adjusted basis. Guardant Health reported a non-GAAP net loss per share of $0.50 for the quarter. This was notably better than the consensus estimate, which anticipated a loss of $0.72 per share. The improvement reflects both strong revenue growth and expanding gross margins, which reached 66% on a non-GAAP basis for the quarter.
Key drivers of the quarterly performance include:
- Oncology Revenue: Grew 30% year-over-year to $189.9 million, supported by a 38% increase in test volume.
- Screening Revenue: Surged to $35.1 million, up from $4.1 million in the prior-year period, driven by approximately 38,000 Shield tests.
- Biopharma & Data Revenue: Increased 9% to $54.0 million.
Market Reaction and Forward Guidance
The market responded favorably to the earnings beat and the company's forward-looking statements. In after-hours trading following the report, Guardant Health's stock price rose approximately 3.6%. This positive movement suggests investors were encouraged by the revenue outperformance, the improved adjusted EPS, and the confident outlook for the coming year.
Management provided full-year 2026 revenue guidance in the range of $1.25 to $1.28 billion, representing growth of 27% to 30%. The midpoint of this range, $1.265 billion, sits above the current analyst sales estimate of $1.273 billion for the year. The guidance anticipates another year of explosive growth for the Shield screening test, with revenue projected between $162 and $174 million, more than double the $79.7 million generated in 2025.
Operational Highlights and Strategic Position
Beyond the financial figures, the earnings press release highlighted several operational milestones that underpin the company's growth narrative:
- Oncology: Received the first companion diagnostic approval for Guardant360 CDx in colorectal cancer and expanded the utility of its Guardant Reveal test for therapy response monitoring.
- Screening: Secured coverage for the Shield colorectal cancer test through TRICARE, the U.S. military's health insurance program, and launched dedicated health system integration teams.
- Strategic Moves: Completed the acquisition of MetaSight Diagnostics to enhance technology capabilities and established a collaboration with Merck to develop companion diagnostics.
Co-CEO Helmy Eltoukhy characterized 2025 as "a great year," citing "breakthrough innovation and best-in-class execution." Co-CEO AmirAli Talasaz noted that the Shield launch has become "one of the most successful diagnostic launches," exceeding the company's own expectations.
Conclusion
Guardant Health's fourth-quarter report paints a picture of a company executing effectively on multiple fronts. The solid revenue beat, improved profitability metrics, and above-consensus guidance for 2026 have been rewarded by the market with a positive after-hours share price move. The results demonstrate continued strong adoption in its established oncology business while the screening segment begins to contribute meaningfully to revenue, potentially setting the stage for a pivotal year of growth and scaling.
For a detailed breakdown of past earnings and future analyst estimates, you can review the data here.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. The author has no position in the mentioned stock. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.